SML2733
RLA8
≥98% (HPLC)
别名:
8-[3-Methoxy-5-[(1E)-2-(4-methoxyphenyl)ethenyl]phenoxy]octanoic acid
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
Quality Level
assay
≥98% (HPLC)
form
powder
storage condition
protect from light
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
O(CCCCCCCC(=O)O)c1cc(cc(c1)\C=C\c2ccc(cc2)OC)OC
InChI
1S/C24H30O5/c1-27-21-13-11-19(12-14-21)9-10-20-16-22(28-2)18-23(17-20)29-15-7-5-3-4-6-8-24(25)26/h9-14,16-18H,3-8,15H2,1-2H3,(H,25,26)/b10-9+
InChI key
MNKZDYGBWDHRMX-MDZDMXLPSA-N
Biochem/physiol Actions
RLA8 is an orally available and potent agonist of peroxisome proliferator-activated receptors (PPARs)-α/γ/δ and G-protein-coupled receptor 40 (GPR40). RLA8 reverses the proregression of pathological changes such as hepatic lipid accumulation, steatosis, inflammation and fibrosis in mice models of nonalcoholic steatohepatitis (NASH). Also, it improves serum HDL cholesterol, reduce hepatic free fatty acid and triglyceride levels, and alleviate insulin resistance.
orally available and potent agonist for PPARs-α/γ/δ and GPR40 that exhibits efficacy to reverse nonalcoholic steatohepatitis and fibrosis
存储类别
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Meng Hua Li et al.
The Journal of pharmacology and experimental therapeutics, 369(1), 67-77 (2019-02-13)
Nonalcoholic fatty liver disease (NAFLD) is a very common chronic hepatic disease, with nonalcoholic steatohepatitis (NASH) as a major and severe subcategory that can lead to cirrhosis and hepatocellular carcinoma, and thereby to a high mortality rate. Currently, there has
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML2733-5MG | 04061841295518 |
| SML2733-25MG | 04061841295501 |
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持